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Gastringastrin, progastrin and glycine-extended gastrin (G-gly), have been detected in
colorectal polyps and tumours, and in the blood of patients with colorectal cancer (CRC), while their
expression is lower in healthy subjects. The surface glycoproteins CD133 and CD44 have been identiﬁed as
possible markers for CRC stem cells. Our aims were to investigate whether progastrin and G-gly are
expressed by CD133-positive cells in human CRC tissues and in the human CRC cell line DLD-1, and to
determine whether this expression is biologically relevant. The great majority of the cells expressing CD133
also expressed gastrin precursors in both DLD-1 cells, which retain a stem cell-like subpopulation, and
human CRC specimens. The CD133high/CD44high/progastrinhigh cells gave rise to larger tumours in SCID mice
compared to CD133low/CD44low/progastrinlow cells. The CD133high/CD44high/progastrinhigh cells displayed
enhanced activation of the signalling molecules JAK2, STAT3, ERK1/2 and Akt, known to regulate the
induction of proliferation and/or survival by gastrin precursors. Moreover, downregulation of the gastrin
gene in DLD-1 cells reduced the expression of cancer stem cell markers and abolished tumour development
in SCID mice. We conclude that gastrin precursors may provide a target for therapies directed against the
cells responsible for tumour development and recurrence.
Crown Copyright © 2009 Published by Elsevier B.V. All rights reserved.1. IntroductionSurgery is a frequent form of treatment for colorectal cancer (CRC)
with a success rate of approximately 40% over a 5 year period [1].
However, recurrence following surgery is a major problem and is often
the ultimate cause of death. Despite the reputation of CRC as a curable
disease, and a thorough characterization of the mutations involved in
the adenoma–carcinoma sequence [2–4] the observation that CRC
remains the second most common cause of cancer-related death
worldwide suggests that currently available treatments are unable to
eliminate all the cancer cells [5,6].
The growth and behaviour of tumours are determined by a small
subpopulation of cancer stem cells, which are able to proliferate
extensively and differentiate into the heterogeneous groups of cells
that form the tumour [7]. These cancer stem cells are resistant to
current therapies targeting the tumour, and are thus responsible for
the recurrence of the pathology [7,8]. Indeed the identiﬁcation of
these cancer stem cells, which are also called tumour-initiating cells, is
a priority in order to develop an effective treatment that will totally
eradicate the cells that are responsible for tumour development and
recurrence.
A subpopulation of cells, positive for the cell-surface glycoprotein
CD133 and representing only a small fraction of the entire primary61 3 9496 1650.
and).
09 Published by Elsevier B.V. All rigcolorectal carcinoma mass, has been independently identiﬁed by two
groups as cancer-initiating cells [9,10]. The CD133-positive cells are
able to maintain themselves in culture in an undifferentiated state, to
initiate tumour growth after xenotransplantation in immunodeﬁcient
mice, and to differentiate into tumours that are phenotypically
identical to the original CRC tissue. In contrast, the CD133-negative
cells, which form most of the primary tumour and thus might
correspond to other cellular differentiation states, were not able to
give rise to tumours. The glycoprotein CD133, which localizes to
membrane protrusions, is thought to participate in the regulation of
membrane topology and is probably not directly related to carcino-
genesis per se. The utility of CD133 as a stem cell marker in CRC has
recently been challenged [11] (see [12] for a balanced review).
Moreover, CD133 is not speciﬁc for CRC as it is also found in
haematopoietic stem cells, in neural progenitor cells and in cancer
stem cells from other tissues including prostate, pancreas and liver
[9,10,13–16]. More recently other markers, such as CD24, CD44, CD166
and Lgr5, have been also identiﬁed for CRC stem cells [17].
The hormone gastrin (Gamide) plays important roles in control-
ling the digestion of food, and in stimulating regeneration of the
mucosal lining of the gastrointestinal tract [18]. Moreover, increased
concentrations of the gastrin precursors, progastrin and glycine-
extended gastrin (G-Gly), have been observed in the circulation of
patients with CRC [19–21]. These peptides are also found in 80 to 90%
of colorectal polyps, which represent an early stage in the colorectal
adenocarcinoma sequence [22] but are absent from healthy tissue.hts reserved.
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produced by colorectal tumours while only low concentrations of
Gamide are present. Interestingly, the observation that resection of
the colorectal tumour induces a decrease in the concentration of the
precursors in the blood suggests that the tumour is the source of the
peptides [23].
Our aim here was to investigate whether progastrin or G-gly is
expressed in CD133-positive CRC cells and, if so, the biological
relevance of gastrin expression. We ﬁrst investigated the co-expres-
sion of both gastrin precursors, progastrin and G-gly, with the CRC
stem cell marker CD133 in human primary colorectal tumour tissues
at different stages of differentiation. We then characterized the
expression of gastrins, CD44 and CD133 in the human colorectal
tumour cell line DLD-1, which retains a stem cell-like subpopulation.
Finally, we studied the biological relevance of the expression of gastrin
precursors in the CD133-positive CRC stem cell-like population by
down regulation of the gastrin gene.
2. Materials and methods
2.1. Antibodies
Anti-progastrin and anti-G-gly antibodies have been characterized
and described previously [21]. Brieﬂy, the anti-progastrin antibody
(antiserum 1137) recognises the C-terminal sequence (92–101) of
human progastrin. The anti-G-gly antibody (antiserum 7270) recog-
nises the C-terminal sequence of G-gly, but does not cross-react with
amidated gastrin or cholecystokinin-gly. Anti-JAK2, anti-phosphoJAK2
(Upstate Biotechnology, Charlottesville, VA, USA); anti-phospho-
Tyr705STAT3, anti-p42/44MAPK, anti-phospho-p42/44MAPK, anti-
Akt, anti-phosphoSer473Akt, anti-GAPDH (Cell Signalling Technology,
Genesearch, Arundel, Australia); anti-nanog, anti-STAT3, anti-actin
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse anti-human
CD133/1 and mouse anti-human CD133/1-PE (Miltenyi Biotec Aus-
tralia Pty. Ltd., North Ryde, NSW); anti-cytokeratin 20 (DAKO,
Kingsgrove, Australia); anti-CD44, anti-Lgr5 (Novus Biologicals,
Littleton, CO, USA); AlexaFluor488 anti-rabbit and AlexaFluor546
anti-mouse IgG (Molecular Probes, Eugene, OR, USA), mouse IgG1s-PE
(BD Biosciences, Scoresby, Australia) were from the indicated
suppliers.
2.2. Immunoﬂuorescent staining of tissue-arrays
Tissue-arrays were from BioChain Institute (Hayward, CA, USA).
Antigens on dewaxed sections were retrieved by boiling slides in
10 mM citrate buffer (pH 6) using a microwave oven. After serum
blocking and application of primary antibodies, bound antibodies
were detected with ﬂuorochrome-coupled secondary antibody.
Control slides, where the primary antibody was replaced by diluted
non-immune rabbit IgG, were checked for non-speciﬁc reactivity
before assessment of the staining. Slides were mounted in
ﬂuorescent mounting medium (DAKO, Kingsgrove, Australia) and
analysed on a Leitz DMRBE microscope with a Leica DC camera and
Leica DC viewer software. Images were further assembled using
Adobe Photoshop software. For comparisons, identical concentra-
tions of antibody were used for all samples and the pictures were
taken at identical exposure times, gamma correction and gain
values.
2.3. Cell culture and growth conditions
The human colorectal tumour cell line DLD-1 was grown in
RPMI 1640 medium supplemented with 10% foetal bovine serum at
37 °C in a 95% air, 5% CO2 atmosphere. Since the holoclones were
very adherent, in order to recover the entire population of the cell
line, cells were dissociated by trypsin treatment and scrapingbefore re-plating. DLD-1 VO and AS cells have been described
previously [24].
2.4. Immunoﬂuorescent staining of cells
DLD-1 cells were grown in 12-well plates containing coverslips and
examined by phase contrast microscopy as colonies developed. Cells
were ﬁxed in 2% paraformaldehyde, permeabilized with ice-cold
methanol, and blocked with 1% FBS in PBS (containing 1 mM Ca2+,
1 mMMg2+). The incubations with primary and secondary antibodies
were performed according to standard immunoﬂuorescent methods.
Slides were mounted in ﬂuorescent mounting medium (DAKO).
Immunoﬂuorescent intensity was analysed in at least three indepen-
dent experiments using the image analyser ImageQuantwith Total Lab
software (GE Healthcare, Rydalmere, Australia) as previously
described [25]. Brieﬂy, the size of region of interest (ROI) for the
quantiﬁcation of the intensity was established on a fully stained zone
of a cell from a holoclone. At least 5measurements were performed on
fully stained ROI of the same size for cells from both holoclones and
paraclones. The data represent an averaged intensity of the 5 ROI
quantiﬁed for each type of colony.
2.5. Isolation of the paraclone and holoclone cells
As described previously [26], the DLD-1 cells were plated at very
low densities in 200-mm Petri dishes for identiﬁcation of colonies
classiﬁed as holoclones (i.e., the putative stem cell colonies predicted
to contain cells able both to self-renew and to give rise to amplifying
cells) and paraclones. These colonies were isolated with cloning rings,
their cells dissociated in trypsin/EDTA, washed and resuspended in
PBS, then counted and diluted appropriately for the xenograft
experiment.
2.6. Flow cytometry
Cells were harvested using PBS containing EDTA and 2% glucose.
The cells were incubated in PBS containing 2% FBS with PE-conjugated
anti-human CD133/1 antibody (Miltenyi Biotec Australia), ﬁxed in 2%
paraformaldehyde-PBS, and then permeabilized with a 0.125%
saponin-PBS buffer, incubated in 2% FBS in PBS with the anti-
progastrin or anti-G-gly antibody and then with the AlexaFluor488
anti-rabbit antibody. Mouse IgG1s-PE was used as isotype control.
Samples were analysed using a FACSDiva ﬂow cytometer and
FACSDiva software (BD Biosciences).
2.7. Western blot analysis
Cells were washed once with PBS and then with buffer A (50 mM
HEPES, pH 7.5, containing 150 mM NaCl, 10 mM EDTA, 10 mM
Na4P2O7, 100 mM NaF, 2 mM Na3VO4). Cells were homogenized in
lysis buffer (buffer A containing 1% Nonidet P 40, 0.5 mM PMSF, 20 μM
leupeptin, 10 μg/ml aprotinin) for 15 min at 4 °C. Proteins were
separated by SDS-PAGE and transferred to nitrocellulose membranes.
Membranes were blotted with the indicated antibodies. Proteins were
visualized using an ECL kit (GE Healthcare).
2.8. Xenografts
Animals were studied under protocols approved by the Austin
Health Animal Ethics Committee. SCID mice were inoculated
subcutaneously on either hind ﬂank with 50 μL PBS containing
5×106 DLD-1 cells (Holoclone or paraclone cells, VO or AS cells) as
indicated in Figs. 2 and 6. Mice were monitored for tumour
development for 21 days, and then humanely killed. Xenografts
were excised and tumour volume was measured with digital calipers,
using the formula: volume=(length×width2) /2.
Table 1
Co-expression of gastrin precursors and the colon cancer stem cell marker CD133 in
human colorectal tumours
Differentiation Number
Trs
Number of positive Tumours
Staining
ProG G-gly CD133 Co-staining
ProG and
CD133
Co-staining
G-gly and
CD133
Well 24 20 15 17 16 14
83.2% 62.4% 70.7% 66.6% 58.2%
Moderately 22 16 12 14 13 12
72.6% 54.5% 63.6% 59% 54.5%
Poorly 10 8 3 4 4 3
80% 30% 40% 40% 30%
ND 4 4 4 4 4 4
100% 100% 100% 100% 100%
Total 60 48 34 39 37 33
80% 56.7% 65% 61.7% 55%
ProG: Progastrin, Number Trs: Number of tumours, ND: Not determined.
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Means (±SEM) were calculated and Students' t-tests were
performed using GraphPad Prism (GraphPad, San Diego, CA, USA).Fig. 1. Co-expression of gastrin precursors with the stem cell marker CD133 in human colo
Hayward, CA, USA) were ﬁxed and stained with the indicated antibodies against CD133 and
analysed on a Leitz DMRBEmicroscope with a Leica DC camera and viewer software. For com
were taken at identical exposure times, and gamma correction and gain values. Photog
magniﬁcation 50×).The statistical signiﬁcance is indicated by the following symbols: ⁎⁎⁎,
Pb0.001; ⁎⁎, 0.001bPb0.01; ⁎, 0.01bPb0.05; ns: PN0.05.
3. Results
3.1. Co-expression of gastrin precursors and the CRC stem cell marker
CD133 in human primary colorectal tumours
CD133 expression is not restricted to stem cells. However, different
epitopes of CD133 with differing glycosylation states have been
identiﬁed, and the AC133/1 epitope, which was used for the
characterization of the CRC stem cells from primary tumours in two
previous studies [9,10], was shown to be speciﬁcally highly expressed
in stem cells or progenitor cells. Furthermore expression of the AC133/
1 antigen varies as a function of the cellular differentiation state and is
restricted to non-differentiated cells [27].
The co-expression of progastrin or G-gly with CD133 was ﬁrst
investigated by co-immunoﬂuorescent staining of a CRC tissue array
which contained sixty specimens fromprimary tumourswith different
differentiation stages (Table 1). Progastrin, G-gly and CD133 staining
was observed in 48, 34 and 39 tumours, respectively. In most of the
CRC specimens, progastrin and G-gly were produced by several
cells in the mucosa while only a few cells expressed CD133 (Fig. 1).rectal cancers. Tissue arrays of human colorectal tumour samples (BioChain Institute,
progastrin (A) or G-gly (B) using standard immunoﬂuorescent techniques. Slides were
parisons, identical concentrations of antibody were used for all samples and the pictures
raphs from representative ﬁelds for each differentiation state are shown. (original
480 A. Ferrand et al. / Biochimica et Biophysica Acta 1793 (2009) 477–488However, most of the cells that expressed CD133 also stained for
progastrin or G-gly. Indeed, co-staining for progastrin or G-gly and
CD133 was found in 37 (94.9%) or 33 (84.6%) specimens,
respectively, out of the 39 tumour specimens staining for CD133.Fig. 2. DLD-1 cells retain a stem cell subpopulation. (A) Morphology. Photograph of the DLD
paraclone (P) are indicated by the plain, dashed and dotted arrows, respectively. (B) Immuno
were ﬁxed, permeabilized and stained with DAPI and antibodies against the stem cell
housekeeping protein GAPDH, using standard immunoﬂuorescent techniques. Slides were a
using the image analyser Biocom as previously described [25]. Representative photographs fr
represent the mean±SEM (n= 3) and are expressed as fold stimulation of expression compar
t-test). HoloC, holoclone; ParaC, paraclone. (C) Tumorigenicity. SCID mice were inoculated su
for tumour development. After 21 days xenografts were excised and tumour volume was mThe proportion of co-stained cells was higher in moderately and
poorly differentiated tumours than in well differentiated tumours.
When staining was observed, the co-expression of gastrin pre-
cursors and CD133 in the same cells was even more obvious in-1 cell line in culture (original magniﬁcation 40×). A holoclone (H), meroclone (M) and
ﬂuorescent staining. DLD-1 cells were grown in 6-well plates containing coverslips. Cells
markers Nanog, CD133 and CD44, the differentiation marker cytokeratin 20, or the
nalysed as described in the legend to Fig. 1. Immunoﬂuorescent intensity was analysed
om one of three independent experiments are shown (original magniﬁcation 50×). Data
ed to holoclone. ⁎⁎⁎ Pb0.0001; ⁎⁎ 0.001bPb0.01; ⁎ 0.01bPb0.05; ns PN0.05 (Students'
bcutaneously with holoclone or paraclone cells on opposite hind ﬂanks, and monitored
easured with digital calipers. Data are presented as means±SEM. (⁎⁎: P=0.003; n=4).
Fig. 3. Gastrin precursors are highly expressed in the stem cell subpopulation. DLD-1 cells were grown in 6-well plates containing coverslips. Cells were ﬁxed, permeabilized and
stained with the indicated antibodies and DAPI using standard immunoﬂuorescent techniques. Slides were analysed as described in the legend to Fig. 1. Immunoﬂuorescent intensity
was analysed using the image analyser Biocom as previously described [25]. Representative photographs from one of three independent experiments are shown at an original
magniﬁcation of 10× (A) or 50× (B). Plain, dashed and dotted arrows represent holoclones, meroclones and paraclones, respectively. Data represent the mean±SEM (n=3) and are
expressed as fold stimulation of expression compared to holoclone. ⁎⁎⁎ Pb0.0001; ⁎⁎ 0.001bPb0.01; ⁎0.01bPb0.05; ns PN0.05 (Students' t-test).
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shows that the great majority of the CD133-positive colorectal
tumour cells express gastrin precursors throughout the different
stages of the development of human colorectal cancers.
3.2. The human CRC cell line DLD-1 retains a stem cell subpopulation
In order to investigate the biological relevance of expression of
gastrin precursors by the CD133-positive CRC cells, we used the
human CRC cell line DLD-1, which retains a stem cell subpopulation
(Fig. 2). As described recently for several cancer cell lines [26,28,29]
the DLD-1 cell line displayed a range of colony morphologies, from
holoclones (H-plain arrow) formed by small, densely packed cells, to
paraclones (P-dotted arrow) formed by spreading, loosely packed,
irregular cells and representing the majority of the cell population
(Fig. 2A). Meroclones (M-dashed arrow) corresponded to an
intermediate morphology. Moreover, as was also reported in the
above mentioned studies [26,28,29] the holoclones were more
adherent than the other clones and were able, after clonal
expansion, to give rise to the entire cell population including the
three different clonal morphologies (data not shown). Finally, when
stained with DAPI in order to visualize the nucleus (Fig. 2B),
holoclones had small uniform nuclei while the paraclones displayed
variable nuclear size, shape and spacing as previously described. As
in the previous studies these different criteria were used to
discriminate holoclones, which have been identiﬁed as the stem
cell subpopulation [26,28,29], from the paraclones, which were
considered to be late-amplifying cells. Holoclones have been
reported to display a stronger staining than paraclones for proteins
shown to be more highly expressed in normal stem cells [26,28,29].
In order to further conﬁrm the stem cell character of the cells
forming the holoclones, DLD-1 cells were stained for Nanog.
Maintenance of a stem cell subpopulation through multiple passages
of cells indicates the persistence of the key stem cell property of
asymmetrical division [7] Nanog is a transcription factor, localized to
the cell nucleus, which plays key roles in the self-renewal and
maintenance of pluripotency in embryonic stem cells [30]. Nanog
overexpression in murine embryonic stem cells is shown in Fig. 2B.
Nanog expression was more than four fold higher in holoclones
compared to paraclones (P=0.0002, n=3). Merging of the DAPI and
Nanog immunoﬂuorescence conﬁrmed the nuclear localisation of
Nanog.
Interestingly, as reported by Ricci-Vitiani and co-workers for the
CD133-positive CRC stem cells puriﬁed from human tumour tissues
[9] the holoclones displayed a high expression of CD133 and low
expression of the differentiationmarker cytokeratin 20. In contrast the
paraclones that stained poorly for CD133 showed good staining for
cytokeratin 20, as described previously for the CD133-negative
colorectal tumour cells [9]. CD44 has also been reported to be highly
expressed in the CRC stem cell population [31,32]. In agreement with
these observations, holoclones showed a stronger staining than
paraclones for this CRC stem cell marker (P=0.003, n=3). No
difference between the different clone types was observed for
GAPDH expression (P=0.34, n=3) (Fig. 2B).
Finally, the tumorigenicity of cells isolated either from holoclones
or paraclones was compared in SCID mice. After isolation of cells from
the different clones as previously described [26], cells were injected
on either ﬂank of the same animal (Fig. 2C), and tumour growth was
followed. After 21 days the tumours obtained from holoclone-derived
cells, which stained strongly for CD133 and CD44, were signiﬁcantly
bigger in each mouse than the tumours arising from paraclone-
derived cells, which stained only weakly for CD133 and CD44. The
observation that cells forming the holoclones have a greater capacity
to give rise to tumours than the cells forming the paraclones is
consistent with the conclusion that the holoclones represent a stem
cell-like population.3.3. Gastrin precursors are mainly expressed in the stem cell-like
population of the human tumour cell line DLD-1
The gastrin precursors, progastrin and G-gly, have been detected in
CRC and in the blood of patients with CRC although they are absent
from healthy colorectal tissue [22]. Moreover, the observation that
tumour resection induced a decreased concentration of gastrin
peptides in the blood of CRC patients suggested that the peptides
were synthesized by the tumour itself. We previously detected the
expression of signiﬁcant amounts of progastrin and G-gly, but only a
negligible amount of Gamide, in DLD-1 cells by radioimmunoassay
[24]. Gastrin precursors have also been shown to promote the
proliferation of this cell line [33].
DLD-1 cells were therefore stained for gastrin peptides by
immunoﬂuorescence. As shown at 10× (Fig. 3A) and 50× (Fig. 3B)
magniﬁcation, holoclones displayed a signiﬁcantly stronger expres-
sion of both progastrin (10 fold higher Pb0.0001, n=3) and G-gly (four
fold higher P=0.0004, n=3) (Fig. 3B bottom panel) than paraclones
which stained very poorly, if at all. Meroclones showed an inter-
mediate expression of both peptides. In agreement with the previous
radioimmunoassay data, DLD-1 cells stained only very weakly for the
mature hormone, Gamide, and no difference was observed between
the different clone types.
3.4. Speciﬁc activation in holoclones of the signalling pathways
responsible for growth-promotion by gastrin precursors in vivo
The in vivo activation of JAK2, STAT3, ERK and Akt has been
described previously in the proliferating colonic mucosa of transgenic
hGAS and MTI/G-gly mice, which overexpress progastrin or G-gly,
respectively [25]. Blockade of these pathways resulted in a decreased
proliferation/survival rate of isolated colonic epithelial cells in primary
culture [25]. The expression and activation levels of these molecules
were therefore analysed by immunoﬂuorescent microscopy of DLD-1
cells using antibodies speciﬁc either for the total or the activated form
of these proteins (Fig. 4). No major difference was observed in the
expression levels of total JAK2, ERK and Akt between holoclones and
paraclones. However, the expression of the transcription factor STAT3
was signiﬁcantly higher in holoclones than in paraclones (P=0.007,
n=3). Moreover, holoclones consistently displayed a signiﬁcantly
higher staining of the activated forms of JAK2, STAT3, ERK and Akt. It
was particularly interesting to note that in the holoclones the active
tyrosine-phosphorylated form of the transcription factor STAT3 was
detectable, by merging of the DAPI and phospho-STAT3 immuno-
ﬂuorescence, in the nucleus where it regulates gene transcription
(Fig. 4).
3.5. Correlated expression of gastrin precursors and the CRC stem cell
marker CD133 in DLD-1 cells
Since the holoclones highly expressed both CD133 and gastrin
precursors, the coexpression of CD133 and progastrin or Ggly in DLD-1
cells was analysed by immunoﬂuorescence with appropriate anti-
bodies (Fig. 5A). The cells were ﬁxed in 2% paraformaldehyde-PBS,
stained for CD133 using the antibody directed against the AC133/1
antigen, and then permeabilized and stained for gastrin precursors.
Strong co-staining of CD133 and both gastrin precursors was observed
in the holoclones which contain a stem cell-like population, while
weak or no co-staining was found in the meroclones and paraclones,
respectively.
In order to further characterize the co-expression of progastrin or
G-gly with CD133, a FACS analysis was performed (Fig. 5B). The cells
were stained for cell surface CD133 using the antibody directed
against the AC133/1 antigen, ﬁxed in 2% paraformaldehyde-PBS, and
then permeabilized and stained for cytoplasmic gastrin precursors.
Cell staining was analysed cytoﬂuorimetrically (Fig. 5B). Negative
Fig. 4. Holoclones display greater activation of JAK2, STAT3, ERK and Akt than paraclones. DLD-1 cells were grown in 6-well plates containing coverslips. Cells were ﬁxed,
permeabilized and stained with the indicated antibodies and DAPI using standard immunoﬂuorescent techniques. Slides were analysed as described in the legend to Fig. 1.
Representative micrographs from one of three independent experiments are shown (original magniﬁcation 50×). Data represent the mean±SEM (n=3) and are expressed as fold
stimulation of expression compared to holoclone. ⁎⁎⁎ Pb0.0001; ⁎⁎ 0.001bPb0.01; ⁎0.01bPb0.05; ns PN0.05 (Students' t-test).
483A. Ferrand et al. / Biochimica et Biophysica Acta 1793 (2009) 477–488control samples were used to set gates for further analysis, such that
99% of the total population was in the lower left quadrant. As shown
for a representative experiment in Fig. 5B, approximately 20% of the
total DLD-1 cell population expressed CD133. Moreover, most of the
cells expressing CD133 also co-stained for progastrin (18.7±0.8% of
the total DLD-1 cell population, n=3) or G-gly (13.1±1.9% of the total
DLD-1 cell population, n=3). No signiﬁcant difference was found
between the percentage of CD133 co-expression with either progas-
trin or G-gly (P=0.052). This observation conﬁrms that the holoclones,
which correspond to the stem cell-like subpopulation in the tumour
cell line, strongly express progastrin and G-gly as well as CD133.3.6. Reduction of gastrin gene expression induces a dramatic decrease in
the expression of the colorectal stem cell markers CD133, CD44 and Lgr5,
and inhibits xenograft development in SCID mice
Stable transfection of DLD-1 cells with antisense (AS) gastrin
constructs induced a change of morphology, as the AS cell population
no longer displayed the three types of clones and all the cells appeared
to be widely spread and closely attached together (Fig. 6A), and
resulted in a signiﬁcant, although not complete, reduction of gastrin
expression (Fig. 6B). As previously reported, the observation that
reduction of gastrin peptide expression restored membrane
Fig. 5. Co-expression of gastrin precursors with the CRC stem cell marker CD133 in DLD-1 cells. (A) DLD-1 cells were grown in 6-well plates containing coverslips. Cells were ﬁxed,
stained for CD133, and then permeabilized and stained with the indicated gastrin precursor antibodies using standard immunoﬂuorescent techniques. Slides were analysed as
described in the legend to Fig. 1. Representative micrographs from three independent experiments are shown. BF: Bright Field photography. Holoclones, meroclones and paraclones
are indicated by the plain, dashed and dotted arrows, respectively (original magniﬁcation 50×). (B) FACS analysis of the expression of gastrin precursors and CD133 in DLD-1 cells. The
cells were ﬁxed in 2% paraformaldehyde-PBS, stained with the anti-CD133/1-PE antibody, and then permeabilized and stained for gastrin precursors which were detected using
rabbit anti-human primary antibodies and an anti-rabbit Alexa488 antibody. Negative control samples were used to set gates for further analysis, such that 99% of the total population
was present in the lower left quadrant of the dot-plot. One representative experiment from three independent experiments is shown. UL: Upper Left, UR: Upper Right, LL: Lower Left,
LR: Lower Right.
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E-cadherin [24], suggested a modiﬁcation of the differentiation of the
cells. A number of additional markers of stem cell populations have
recently been reported. Haraguchi and coworkers have demonstrated
that within CRC cell lines, only the CD133-positive CD44-positive
population is able to produce tumours [32] while recent studies in
mice suggest that the G-protein-coupled receptor Lgr5 might be
another marker for both colon stem cells and CRC stem cells [34].
Importantly, the expression of these three markers (CD133, CD44 andLgr5) was dramatically reduced in AS cells compared to cells
transfected with the vector only (VO cells) (Fig. 6B, D, F). The decrease
in the expression of these different colon stem cell markers after
major depletion of gastrin peptides by transfection of DLD-1 cells with
an AS gastrin plasmid was conﬁrmed bywestern-blot analysis (Fig. 6C,
E, G). A signiﬁcant reduction of CD133, CD44 and Lgr5 was found in AS
cells, inwhich expressionwas only 18.5±4.0% (P=0.002;n=3), 28.2±2.5%
(P=0.0005; n=3), and 50.2±2.1% (P=0.004; n=3), respectively, of their
expression in VO control cells.
Fig. 6. Down regulation of the gastrin gene in DLD-1 cells modulates DLD-1 differentiation and induces a dramatic decrease in CD133 expression. (A) Morphology. Photographs of the
parental DLD-1 cell line, and the DLD-1 cells transfected either with vector only (VO) or with an antisense (AS) gastrin plasmid in culture (original magniﬁcation 40X). H: holoclones;
P: paraclones. (B, D, F) Immunoﬂuorescent staining. DLD-1 cells transfected with vector only (VO) or with an antisense (AS) gastrin plasmid were grown in 6-well plates containing
coverslips. Cells were ﬁxed and stained with the indicated antibodies using standard immunoﬂuorescent techniques (original magniﬁcation 20× for B and F; 50× for D). Slides were
analysed as described in the legend to Fig. 1. Representative photographs from three independent experiments are shown. (C, E, G) Western-blot analysis. Lysates of DLD-1 VO cells
and AS cells, containing identical protein concentrations, were separated by SDS-PAGE and analysed bywestern-blot with the antibodies against CD133, CD44 or Lgr5. Themembrane
was also probedwith antibodies against actin or GAPDH to correct for unequal loading of proteins. Data are presented asmeans±SEM. IB: Immunoblot. (H) Tumorigenicity. SCIDmice
were inoculated subcutaneously on either hind ﬂank with VO or AS cells as indicated, and monitored for tumour development. After 21 days xenografts were excised and tumour
volume was measured with digital calipers. Data is presented as means±SEM. (⁎⁎: P=0.01; n=4).
485A. Ferrand et al. / Biochimica et Biophysica Acta 1793 (2009) 477–488Two previous studies of the CD133-positive stem cells in primary
colorectal tumours [9,10] elegantly demonstrated that cells that did
not express CD133 lost their ability to develop into tumours when
xenografted in immunodeﬁcient mice. A more recent report demon-
strated that the CD133-positive CD44-positive population within
colorectal tumours was the one able to produce a tumour [32]. The
weak expression of CD133, CD44 and Lgr5 in DLD-1 AS cells, as well asthe morphological changes observed (Fig. 6A), therefore implied that
these cells might have undergone differentiation and lost their stem
cell characteristics. To test this hypothesis, the tumorigenicity of AS
and VO cells was compared in SCID mice. AS or VO cells were injected
on either ﬂank of the same animal (Fig. 6E), and tumour growth was
followed. After 21 days while the VO cells had developed into a
tumour in each mouse, no tumours had developed from the AS cells.
486 A. Ferrand et al. / Biochimica et Biophysica Acta 1793 (2009) 477–488This observation demonstrated that a major reduction of gastrin gene
expression in CRC stem cells abolished their capacity to initiate
tumours.
4. Discussion
The hypothesis has been proposed during the last decade that
cancer tissue, like normal tissue, develops from a stem cell
subpopulation that has the abilities to self-renew and to differentiate
into multiple cell types. The ﬁrst evidence of a cancer stem cell
subpopulation in tumours came from a study in 1994, when Lapidot
and co-workers characterized a subpopulation of CD34+/CD38− cells
in acute myeloid leukaemia capable of initiating the human disease in
immunodeﬁcient mice [35]. These cells possessed the same differ-
entiative and proliferative capacities, and the same self-renewal
potential, as the leukaemic stem cell, and developed into leukaemia
that was histologically similar to the human disease. Since 1994,
cancer stem cells have also been identiﬁed in solid tumours of the
breast, brain, prostate, and more recently colon [9,10]. Two indepen-
dent studies have identiﬁed the CD133-positive cell subpopulation in
CRC as CRC stem cells [9,10] and a recent study reports that CD133
expression in CRC correlates with a poorer survival [36]. However
CD133 is not speciﬁc for CRC stem cells and not all CD133-positive cells
in colorectal cancers are tumorigenic [9,10] More recent studies have
identiﬁed other markers, such as CD44, CD166, ESA, CD24 and Lgr5,
that might be used to identify CRC stem cells [17]. Although these
different surface proteins could be useful targets for therapy directed
against the CRC stem cells, there is still an urgent need to identify
alternative therapeutic targets, which are involved in colorectal
tumour development, that are preferably found only in the cancer
tissue, and that might speciﬁcally regulate the CRC stem cells.
Gastrin precursors are good candidates for such targets. These
peptides, which are known to regulate the growth and survival of
human colorectal carcinoma cells, are absent from healthy colorectal
mucosa but are overexpressed in polyps and tumours [18]. We now
report that analysis of sixty primary human colorectal tumours at
different differentiation stages revealed the co-expression of progas-
trin or G-gly with the cancer stem cell marker CD133 in 94.9% and
84.6%, respectively, of the specimens. We therefore explored the
biological relevance of gastrin precursor expression in the human CRC
cell line DLD-1, which has previously been shown by radioimmu-
noassay to express signiﬁcant amounts of progastrin and G-gly but
only a negligible amount of Gamide [24].
Primary keratinocytes display three typical clonal morphologies
represented by holoclones, meroclones, and paraclones [37]. Holo-
clones contain self-renewing stem cells, while meroclones and
paraclones containmoremature and differentiated cells. Interestingly,
even after many passages human epithelial cancer cells in clonal
cultures also form holoclones, meroclones, and paraclones. Moreover
tumour cell holoclones have been shown to harbour stem-like cells or
cancer stem cells. Locke et al. have shown that stem cells are also
present in head and neck squamous cell carcinomas, the prostate cell
line DU145 and the breast cancer cell line MCF7 [26]. More recently, Li
and colleagues have demonstrated that holoclones in the human
prostate carcinoma cell line PC3 contain self-renewing tumour-
initiating cells [29]. Here, we report that the human primary CRC
cell line, DLD-1, also displays the same three types of clones.
Importantly the holoclones resulted in much larger tumours than
paraclones when injected into SCID mice.
The holoclones, when compared to paraclones, strongly express
several CRC stem cell markers, including CD133 and CD44. CD133
mRNA expression in the DLD-1 cell line has recently been reported
by Ieta and colleagues in a survey of several CRC cell lines [38].
Moreover, as described for CD133-positive cancer stem cells isolated
from human CRC [9], the DLD-1 CD133high cells only weakly express
the differentiation marker cytokeratin 20. Similarly, the observationof higher staining for stem cell markers by holoclones was made in
the breast cancer cell line MCF7 which also displays the three clone
morphologies. MCF7 holoclones strongly expressed CD44, the sur-
face marker used to identify the breast cancer stem cells in tumour
tissue [39]. Recently, Dalerba et al. reported that CRC cells expressing
CD44 also displayed stem cell properties as they were able to engraft
in vivo in SCID mice. The resulting tumours maintained a
differentiated phenotype and reproduced the entire cellular hetero-
geneity of their parental lesions [31]. A more recent study showed
that within the tumour cells, selection for the CD133-positive CD44-
positive population efﬁciently enriched colorectal stem cells [32].
The DLD-1 cell line expresses CD44 [40] and we demonstrate here
that holoclones also display a higher expression of the protein than
paraclones (Fig. 2B). We also found in the DLD-1 cell line that the
cells highly expressing CD133 and CD44 (the holoclone population)
frequently co-express either progastrin or G-gly. Interestingly, the
approximate linearity of the relationship between expression of
CD133 and progastrin or G-gly (Fig. 5B) suggests that the expression
of the two genes may be coordinated. The observation that stable
transfection of DLD-1 cells with antisense (AS) gastrin constructs
resulted in a dramatic decrease in CD133 expression is consistent
with this suggestion (Fig. 6C).
As previouslymentioned, JAK2, STAT3, ERK and Akt are activated in
vivo in the proliferating colonic mucosa of transgenic mice over-
expressing either progastrin or G-gly [25]. Moreover, blockade of
these pathways resulted in a decreased proliferation/survival rate of
isolated colonic epithelial cells in primary culture [25]. On the other
hand, the resistance of cancer stem cells to chemotherapy or
radiotherapy is thought to be responsible for tumour recurrence [7].
In this context it is relevant to note that the Akt pathway is well
established as an important regulator of cell survival. For instance, the
resistance of CD133-positive hepatocarcinoma stem cells to che-
motherapy with doxorubicin and 5-ﬂuorouracil has been shown to be
preferentially mediated by activation of the Akt pathway [41].
Moreover, the transcription factor STAT3 is now thought to be a
predictivemarker of resistance to chemotherapy [42]. Inhibition of the
STAT3 pathway downregulates the expression of survival proteins and
restores cellular sensitivity to signalling by cell-death receptors.
Recent studies have reported an abnormally increased STAT3 activa-
tion in ovarian cancer cells resistant to paclitaxel treatment [43] and
Niu and co-workers have demonstrated that STAT3 plays a protective
role in CRC cells in which its inactivation enhances UV-induced cell
death [44]. We observed in DLD-1 cells that the stem cell-like
subpopulation, which expresses progastrin and G-gly, also displays
enhanced activation of the Akt and STAT3 signalling molecules (Fig. 4),
which are all known to regulate the proliferation and/or survival
induced by gastrin precursors in vitro [45] and in vivo [25]. The
evidence is therefore consistent with the hypothesis that gastrin
precursors might participate in increasing the survival of the DLD-1
stem cell population by autocrine regulation, and may therefore
contribute to the resistance of cancer stem cells to chemotherapy or
radiotherapy.
In contrast, downregulation of the expression of gastrin peptides in
DLD-1 AS cells correlated with amorphological change and a dramatic
decrease in CD133, CD44 and Lgr5 expression. Since down-regulation
of CD133 and CD44 upon differentiation has been previously
described in the human CRC cell lines Caco-2 [46] and HT29 [32],
this observation suggests a reduction in gastrin concentration may
have induced differentiation. In this context it is interesting to note
that progastrin regulates the beta-catenin/Tcf-4 pathway, a major
regulator of the differentiation process in colon [47], and that down-
regulation of gastrin increases the numbers of intestinal goblet cells in
APCΔ14 mice [47]. The present observation that the down regulation
of the gastrin gene in DLD-1 cells, where gastrin peptides are found
predominantly in the CRC stem cell population, prevented the
development of tumours in SCID mice (Fig. 6H) further suggests that
487A. Ferrand et al. / Biochimica et Biophysica Acta 1793 (2009) 477–488gastrin gene expression in the CRC stem cell is crucial for its ability to
give rise to tumours. Interestingly, since the AS cells can be readily
expanded in culture, the absence of tumorigenic activity is not a
consequence of loss of the capacity for self-renewal. As the AS cells are
still able to proliferate, the dramatic decrease observed in the
expression of the cancer stem cell markers, and the loss of their
capacity to give rise to tumours, indicate a change in the differentia-
tion status of the AS cells, compared to the holoclone subpopulation
within the parental DLD-1 cell line.
The role of CD133 as a CRC stem cell marker has recently been
challenged [11]. In contrast to all the previous studies performed on
human primary colorectal tumour tissues or cells lines which
described the CD133-positive population within the colorectal
primary tumours as cancer stem cells [9,10] the authors argued that
CD133 expression in colon is not restricted to stem cells and that both
the CD133-positive and -negative cell populations from metastatic
tissues are able to give rise to tumours in immunodeﬁcient mice. As
discussed by LaBarge and Bissel [12], Shmelkov and coworkers did not
actually test the functional tumour-initiating capacity of the CD133-
negative populations in the primary tumours they analysed and thus
did not conclusively demonstrate that CD133 expression does not
segregate with the cancer stem cell population in the primary
tumours [11]. Considering the discrepancy between this recent
study analysing the cancer stem cell capacity in metastatic tumours
and previous reports performed on primary tumours, a differencemay
exist between the cancer stem cell populations of primary and
metastatic tumours. The difference in views regarding the suitability
of CD133 as a CRC stem cell marker emphasizes the need to validate
additional function molecular markers of CRC stem cells. In regard to
the different studies characterising the expression of CD133 in
primary tumours, LaBarge and Bissel [12] suggest that a more
appropriate marker of the CRC stem cells in the primary tumours
would be their level of expression of CD133, with a high level
corresponding to a stem cell population. This suggestion is in
accordance with our observation within the DLD-1 population
where the holoclones strongly express CD133, while the paraclones
show only weak expression of the glycoprotein, and the meroclones
present an intermediate staining. Interestingly, as shown in Fig. 5, we
found a correlation of expression between CD133 and gastrin
precursors in this cell line. However, downregulation of CD133 in AS
cells does not appear to lead to metastatic cells since, as mentioned
above, the reduction of gastrin peptide expression strengthen cell–cell
adhesion by restoring membrane localisation of zonula occludens-1
(ZO-1), occludin, beta-catenin and E-cadherin [24]. Moreover,
tumours were not observed elsewhere in the SCID mice injected
with DLD-1-AS cells.
In conclusion, our study demonstrates, in CRC tissues at different
pathological stages and in the human CRC cell line DLD-1, that CRC
cells which are putatively identiﬁed as stem cells on the basis of their
high expression of CD133, CD44 and lgr5 also express the gastrin
precursors, progastrin and G-gly. Furthermore the ability of DLD-1
cells to grow into tumours is largely dependent on gastrin gene
expression. As a consequence, gastrin precursors could represent an
excellent therapeutic target in the cells responsible for tumour
development and recurrence.
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